Why Influenza Subclade K Became Dominant—And What It Means for Influenza Vaccine Strategy
A new study by EVA Therapeutics founder Dr. Annie De Groot reveals why seasonal vaccines elicited protective antibody responses yet failed to stop the strain’s rapid spread.
